Welcome to LookChem.com Sign In|Join Free

CAS

  • or

666828-90-6

Post Buying Request

666828-90-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

666828-90-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 666828-90-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,6,6,8,2 and 8 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 666828-90:
(8*6)+(7*6)+(6*6)+(5*8)+(4*2)+(3*8)+(2*9)+(1*0)=216
216 % 10 = 6
So 666828-90-6 is a valid CAS Registry Number.

666828-90-6Upstream product

666828-90-6Relevant articles and documents

1-[(Imidazolidin-2-yl)imino]-1H-indoles as new hypotensive agents: synthesis and in vitro and in vivo biological studies

Kornicka, Anita,Wasilewska, Aleksandra,S?czewski, Jaros?aw,Hudson, Alan L.,Boblewski, Konrad,Lehmann, Artur,Gzella, Karol,Belka, Mariusz,S?czewski, Franciszek,Gdaniec, Maria,Rybczyńska, Apolonia,B?czek, Tomasz

, p. 400 - 410 (2017/04/03)

A series of 1-[(imidazolidin-2-yl)imino]-1H-indole analogues of hypotensive α2-AR agonists, 1-[(imidazolidin-2-yl)imino]-1H-indazoles, was synthesized and tested in vitro for their activities at α1- and α2-adrenoceptors as well as imidazoline I1 and I2 receptors. The most active 1-[(imidazolidin-2-yl)imino]-1H-indoles displayed high or moderate affinities for α1- and α2-adrenoceptors and substantial selectivity for α2-adrenoceptors over imidazoline-I1 binding sites. The in vivo cardiovascular properties of indole derivatives 3 revealed that substitution at C-7 position of the indole ring may result in compounds with high cardiovascular activity. Among them, 7-fluoro congener 3g showed the most pronounced hypotensive and bradycardic activities in this experiment at a dose as low as 10?μg/kg i.v. Metabolic stability of the selected compounds of type 3 was determined using both in vitro and in silico approaches. The results indicated that these compounds are not vulnerable to rapid first-phase oxidative metabolism.

PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS

-

Page/Page column 123-124, (2008/12/04)

This invention is directed to a compound wherein R1, R2, R3, R4 and L1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 666828-90-6